GenSight Biologics Chief Technology Officer Scott Jeffers will be speaking in Boston, MA, on a topic of critical importance to companies developing ATMPs.
GenSight Biologics
Recherche en biotechnologie
Paris, Ile de France 8 643 abonnés
Applying pathbreaking science to transform the lives of patients with severe retinal neurodegenerative diseases
À propos
GenSight Biologics is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics for retinitis pigmentosa, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. GenSight Biologics’ lead product candidate, GS010, is in Phase III trials in Leber’s Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible low vision and legal blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.
- Site web
-
http://www.gensight-biologics.com
Lien externe pour GenSight Biologics
- Secteur
- Recherche en biotechnologie
- Taille de l’entreprise
- 11-50 employés
- Siège social
- Paris, Ile de France
- Type
- Société cotée en bourse
- Fondée en
- 2013
Lieux
-
Principal
Obtenir l’itinéraire
74 rue du Faubourg Saint Antoine
75012 Paris, Ile de France, FR
Employés chez GenSight Biologics
-
William Monteith
-
Jan Eryk Umiastowski
-
Scott Jeffers Ph.D.
Chief Technology Officer | Gene Therapy Innovation, Process Development, Global Leadership | I help biotech reach patients faster by optimizing CMC…
-
Marion Ghibaudo, PhD
Chief Technical Officer Medical Device at GenSight Biologics
Nouvelles
-
The second issue of our newsletter for retail investors is now available at https://lnkd.in/g7xqiSxw . In this issue (currently only in French), Magali Gibou, VP Regulatory Affairs and Quality Assurance, explains some of the intricacies of the French early access (AAC) program.
-
-
Stories like Tim's sustain our team and keep us highly motivated ... (Video by BFM TV; video in French) A visually impaired Frenchman regains his sight thanks to gene therapy. https://lnkd.in/eSawcUTr "It's a huge step forward -- it allows me to see faces again." -- Tim, LHON patient
Pages similaires
Financement
GenSight Biologics
15 rounds en tout
Voir plus d’informations sur Crunchbase
Dernier round
Capital après introduction en Bourse
Lien Crunchbase externe pour la dernière levée de fonds
3 043 740,00 $US